Dr. Jasmin Hefendehl, University of British Columbia

  • Jasmin Hefendehl
Dr. Jasmin Hefendehl, University of British Columbia2017-01-06T09:55:43+00:00

Project Description

Altered glutamate dynamics in a mouse model of Alzheimer’s disease: Novel early biomarkers with therapeutic potential


Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. With no cure available, it imposes a major burden on society. In AD, a protein called amyloid beta accumulates into plaques in the brain. This event is an early and predictive marker for AD and can be detected up to 20 years before clinical symptoms arise.

We are exploring the dysfunction and hyperactivity of various cell types in the presence of amyloid plaques. We will investigate the possible role of altered glutamate dynamics in mouse models of AD. Fluorescent labelling will shed light on changes in glutamate signalling in awake and behaving AD mice. We will also test whether Ceftriaxone can restore normal glutamate dynamics in these mice.

Ultimately, our work with AD mouse models and novel glutamate imaging could shed light on possible drug targets and enable early intervention for people with Alzheimer’s disease.


Dr. Jasmin Hefendehl was one of the exceptional scientists identified to be a research grant recipient for the 2015 Trainee Partnership Award, co-funded by The Pacific Alzheimer Research Foundation (PARF) and the Michael Smith Foundation for Health Research (MSFHR). > Learn more…

Are you a scientist working in the areas of Alzheimer's disease and dementia? Our foundation might be able to support your research through our grant program.


Projects like these are critical to helping find a cure for Alzheimer's disease. Your much needed and appreciated support will help provide the necessary funding.